Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1152.44 +14.62 (1.28%)
Previous Close $1137.82    52 Week High $88.16 
Open $1150.27    52 Week Low $67.88 
Day High $1159.75    P/E 266.77 
Day Low $1138.26    EPS $4.32 
Volume 1,897,937